Qlarity Imaging and Blackford have signed a new pact to improve breast magnetic resonance imaging (MRI) accuracy.
QuantX by Qlarity Imaging differentiates benign from malignant breast lesions by synthesizing 34 radiomic features into a single value. The QuantX Score, derived from analysis of proven lesions, indicates the likelihood of malignancy in a specimen. The FDA-cleared artificial intelligence (AI) also assists radiologists with volumetric and surface area measurements.
Per the new deal, Qlarity will integrate its AI diagnostic software with Blackford’s centralized imaging platform to help radiologists and health care systems achieve better clinical outcomes.
The Qlarity-Blackford partnership is also geared toward reducing breast MRI deployment time, costs, maintenance, monitoring, and support requirements.
"Breast MRI evaluations are one of the more difficult exams for radiologists. Factoring in the current challenges contributing to widespread radiologist burnout, the question is not if technological advancements are needed, but how they can be developed and implemented to add the most value," said Jon DeVries, Qlarity Imaging CEO.
DeVries added, "Partnering with Blackford will help radiologists and their teams overcome current workflow, budget, and productivity challenges, while also providing unique opportunities for innovation with partners to improve the quality of breast cancer screening and diagnosis strategies."
Commenting on its tool’s scope, Qlarity stated QuantX is designed for screening patients at high risk for breast abnormalities. QuantX's clinical trials that earned it FDA approval found it reduced missed cancers by 39% and increased clinical accuracy by 20%.
QuantX is not intended for the primary interpretation of digital mammograms.
"We are delighted that Qlarity's QuantX™ will be available through Blackford's curated marketplace of applications. We look forward to working with Qlarity to provide our customers and channel partners with simplified access to QuantX™ through our dedicated platform, to help drive additional clinical value for patients," said Ben Panter, Blackford Analysis CEO.
